Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix®): Results of two randomized trials - Weston, Wayde M.; Friedland, Leonard R.; Wu, Xiangfeng; Howe, Barbara (Vaccine, 2012)
Keywords: Acellular pertussis vaccine; Age; Aged; Allergy and Immunology; antibodies; Antibodies, Bacterial - blood; Antibodies, Viral - blood; Antigens; children; Confidence intervals; Diphtheria; Diphtheria - prevention & control; Diphtheria toxoid; Diphtheria Toxoid - administration & dosage; Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage; Diphtheria-Tetanus-Pertussis Vaccine - adverse effects; elderly; Elderly vaccination; Humans; immune response; infants; Influenza; Influenza Vaccines - administration & dosage; Influenza Vaccines - adverse effects; Influenza, Human - prevention & control; Licenses; morbidity; Older people; patients; Pertussis vaccination; Postpartum period; Single-Blind Method; Studies; Tdap vaccine; Tetanus; Tetanus - prevention & control; Tetanus toxoid; Tetanus Toxoid - administration & dosage; Vaccination; Vaccines; Vaccines, Acellular - administration & dosage; Whooping cough; Whooping Cough - prevention & control; United States--US; LL; Diphtheria toxoid; D; PT; Tdap vaccine; CI; PRN; GMT; Pertussis vaccination; T; SAE; Tetanus toxoid; Acellular pertussis vaccine; Tdap; HA; GMC; FHA; Elderly vaccination; DTaP; ELISA; geometric mean antibody concentration; diphtheria toxoid; geometric mean antibody titre; paediatric diphtheria toxoid, tetanus toxoid, and acellular pertussis vaccine; reduced antigen content tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine; serious adverse event; tetanus toxoid; filamentous haemagglutinin; lower limit; pertactin; viral haemagglutinin; pertussis toxoid; enzyme-linked immunosorbent assay; confidence interval